AVM
PBLS

Arch Venture Management’s Parabilis Medicines Inc PBLS Stock Holding History

Arch Venture Management’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176M Buy
+6,412,780
New +$177M 15.95% 1

Other funds holding PBLS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Arch Venture Management's PBLS Position: Q2 2026 in Review

Arch Venture Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 6,412,780 shares worth $176M. The stake represents 15.95% of the portfolio and ranks #1 among its holdings.

68 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Arch Venture Management held 6,412,780 shares of Parabilis Medicines Inc worth $176M as of Q2 2026.
  • Parabilis Medicines Inc was a new Arch Venture Management position in Q2 2026.
  • Parabilis Medicines Inc made up 15.95% of Arch Venture Management's portfolio in Q2 2026, its #1 holding.
  • 68 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.